Cargando…

Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint

There is growing evidence that the neurotransmitter norepinephrine (NE) and its sister molecule epinephrine (EPI) (adrenaline) affect some types of cancer. Several recent epidemiological studies have shown that chronic use of beta blocking drugs (which antagonize NE/EPI receptors) results in lower r...

Descripción completa

Detalles Bibliográficos
Autor principal:	Fitzgerald, Paul J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396053/ https://www.ncbi.nlm.nih.gov/pubmed/22807646 http://dx.doi.org/10.2147/CLEP.S33695

Ejemplares similares

Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer
por: Fitzgerald, Paul J
Publicado: (2010)

Who's Afraid of the Big Bad Wolf? Safety of Beta-Blockers in COPD
por: Ambrosio, Giuseppe, et al.
Publicado: (2019)

Endpoints and viewpoints on spatial neglect
por: McIntosh, Robert D., et al.
Publicado: (2022)

Global chemical reactivity parameters for several chiral beta-blockers from the Density Functional Theory viewpoint
por: TALMACIU, MONA MARIA, et al.
Publicado: (2016)

Arginine vasopressin in septic shock: supplement or substitute for norepinephrine?
por: Rehberg, Sebastian, et al.
Publicado: (2009)

Norepinephrine: more of a neurohormone than a vasopressor
por: Myburgh, John
Publicado: (2010)

Arginine vasopressin versus norepinephrine: will the stronger one win the race?
por: Ertmer, Christian, et al.
Publicado: (2006)

Timing of norepinephrine in septic patients: NOT too little too late
por: Rachoin, Jean-Sebastien, et al.
Publicado: (2014)

Treatment of Alzheimer’s Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions
por: Ashford, John Wesson
Publicado: (2019)

EUS-B-FNA: Pulmonologist's viewpoint: Whose tube is it anyway?
por: Vallandramam, Pattabhi Raman Ranganathan, et al.
Publicado: (2015)

Two Perspectives on Dravet Syndrome: Viewpoints from the Clinician and the Caregiver
por: Bluvstein, Judith, et al.
Publicado: (2023)

β1-blocker in sepsis
por: Hasegawa, Daisuke, et al.
Publicado: (2021)

Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight
por: Bhatt, Deepak L, et al.
Publicado: (2001)

Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
por: Ho, Gilbert, et al.
Publicado: (2022)

Norepinephrine May Oppose Other Neuromodulators to Impact Alzheimer’s Disease
por: Fitzgerald, Paul J.
Publicado: (2021)

Beta-Blockers and Cancer: Where Are We?
por: Peixoto, Rita, et al.
Publicado: (2020)

Different perspectives and viewpoints on the postoperative management of EGFR-mutant lung cancer
por: Nakao, Masayuki, et al.
Publicado: (2020)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Beta Blockers and Melanoma
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

β-blockers in septic shock: are we there yet?
por: Cruz, Madalena Coutinho, et al.
Publicado: (2017)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Recently published papers: Renal replacement therapy: which route and how much? Intracerebral haematomas: does the size matter? beta blockers and steroids: will we ever know?
por: Kushakovsky, Vlad, et al.
Publicado: (2008)

Many Drugs of Abuse May Be Acutely Transformed to Dopamine, Norepinephrine and Epinephrine In Vivo
por: Fitzgerald, Paul J.
Publicado: (2021)

Is There a Novel Biosynthetic Pathway in Mice That Converts Alcohol to Dopamine, Norepinephrine and Epinephrine?
por: Fitzgerald, Paul J.
Publicado: (2022)

Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"
por: Fazio, Sergio, et al.
Publicado: (2001)

Perioperative use of beta-blockers
por: Priebe, Hans-Joachim
Publicado: (2009)

Beta-blockers in liver cirrhosis
por: Giannelli, Valerio, et al.
Publicado: (2014)

The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is norepinephrine rather than dopamine
por: Sharma, Vinay K, et al.
Publicado: (2003)

The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is dopamine rather than norepinephrine
por: Vincent, Jean-Louis, et al.
Publicado: (2003)

Viewpoints on the PRIOR statement—a reporting guideline for overviews of reviews
por: Yang, Nan, et al.
Publicado: (2023)

A Clinical-Epidemiological Study on Beta-Blocker Poisonings Based on the Type of Drug Overdose
por: Eizadi-Mood, Nastaran, et al.
Publicado: (2023)

Beta-blocker use and COPD mortality: a systematic review and meta-analysis
por: Etminan, Mahyar, et al.
Publicado: (2012)

Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients
por: Cho, Min Ae, et al.
Publicado: (2020)

Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis
por: Wang, Zexu, et al.
Publicado: (2023)

Helium’s placement in the Periodic Table from a crystal structure viewpoint
por: Kurushkin, Mikhail
Publicado: (2020)

Understanding Creutzfeldt-Jackob disease from a viewpoint of amyloidogenic evolvability
por: Hashimoto, Makoto, et al.
Publicado: (2020)

Calcium-Channel Blockers: An Alternative Therapy to Beta-Blockers for Myocardial Infarction?
por: Hao, Kiyotaka, et al.
Publicado: (2023)

Angiotensin receptor blockers in heart failure after the ELITE II trial
por: Willenheimer, Ronnie
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_92kosrcg5hd1fseulfdp2lf0s0